• BioLineRx and Hemispherian presented preclinical GLIX1 combination results in ovarian cancer at ESMO 2026 on Oct. 23.
• GLIX1 enhanced PARP inhibitor activity across multiple ovarian cancer cell lines without homologous recombination deficiency.
• Low-dose GLIX1 with olaparib inhibited tumor growth in a mouse model, outperforming either drug alone and showing activity comparable to cisplatin.
• An ovarian cancer arm is planned for the expansion phase of GLIX1's ongoing Phase 1/2a glioblastoma trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLineRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN79078) on October 23, 2026, and is solely responsible for the information contained therein.